Further, to investigate whether the anti-tumor effects of the combined treatment are mediated via the inhibition of the Akt/mTOR pathway, the phosphorylation pattern of the members of this pathway were analyzed in the HCC cells treated with BEZ235 and regorafenib for 48 h. Here, MTOR is linked to hepatocellular carcinoma.